We believe that new strategies/agents that aim to reduce erbB3 protein levels, such as the antisense oligonucleotide EZN-3920 [95], the HDAC inhibitor entinostat [96], and the cooperative “sister” miRNAs [97,98] may hold special antitumor activity as the tumor cells won’t have opportunities to develop resistance. The gene discussed is ERBB3; the disease is neoplasm.